methyl-(2-methyl-benzyl)-propyl-amine

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: methyl-(2-methyl-benzyl)-propyl-amine
• 英文别名: Methyl-(2-methyl-benzyl)-propyl-amin；N-methyl-N-[(2-methylphenyl)methyl]propan-1-amine
• 化学式: C₁₂H₁₉N
• 分子量: 177.29
• InChiKey: QALCJLUGJYEPKR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  2-甲基苄溴 在 甲酸 、 水 、 碳酸氢钠 作用下， 生成 methyl-(2-methyl-benzyl)-propyl-amine
  参考文献：
  名称：

  The Ortho Substitution Rearrangement versus β-Elimination of Certain Quaternary Ammonium Ions with Sodium Amide. Extension of the Method of Synthesis of Vicinal Alkyl Aromatic Derivatives¹

  摘要：

  DOI：

  10.1021/ja01634a018

文献信息

• NOVEL TETRAHYDROPYRAZOLO [3,4-b] AZEPINE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS
  申请人：Bolea Christelle

  公开号：US20130267499A1

  公开（公告）日：2013-10-10

  The present invention relates to novel compounds of Formula (I), wherein M, A and Y are defined as in Formula (I); invention compounds are modulators of metabotropic glutamate receptors—subtype 4 (“mGluR 4 ”) which are useful for the treatment or prevention of central nervous system disorders as well as other disorders modulated by mGluR 4 receptors. The invention is also directed to pharmaceutical compositions and the use of such compounds in the manufacture of medicaments, as well as to the use of such compounds for the prevention and treatment of such diseases in which mGluR 4 is involved.

  本发明涉及公式（I）的新化合物，其中M，A和Y如公式（I）中所定义；发明化合物是代谢型谷氨酸受体-亚型4（“mGluR4”）的调节剂，可用于治疗或预防中枢神经系统疾病以及其他受mGluR4受体调节的疾病。本发明还涉及制药组合物以及使用这些化合物制造药物的用途，以及使用这些化合物预防和治疗涉及mGluR4的疾病的用途。
• SUBSTITUTED AMINO TRIAZOLES, AND METHODS USING SAME
  申请人：THE INSTITUTE FOR DRUG DELIVERY

  公开号：US20160297823A1

  公开（公告）日：2016-10-13

  Disclosed are novel substituted amino triazoles of Formula (I), and pharmaceutically acceptable salts thereof. The compounds of Formula (I) are inhibitors of Acidic mammalian chitinase (AMCase) and are useful, in a non-limiting example, for treating asthma. Also provided are pharmaceutical compositions containing at least one compound of the present invention, or a pharmaceutically acceptable salt, hydrate or solvate thereof, and at least one pharmaceutically acceptable carrier, solvent, adjuvant or diluent, and methods of using such compounds and/or compositions to treat asthma and/or to monitor asthma treatment.
• COMPOUND HAVING AFFINITY SUBSTANCE TO SOLUBLE PROTEIN, CLEAVABLE PORTION AND REACTIVE GROUP, OR SALT THEREOF
  申请人：Ajinomoto Co., Inc.

  公开号：US20200190165A1

  公开（公告）日：2020-06-18

  The present invention provides a technique enabling modification of a soluble protein and in particular regioselective modification of a soluble protein. More specifically, the present invention provides a compound having an affinity substance to a soluble protein, a cleavable portion, and a reactive group represented by the following Formula (I): A-L-B-R  (I) wherein A is an affinity substance to a soluble protein; L is a cleavable linker which is a divalent group comprising a cleavable portion; B is (a) a divalent group comprising a bioorthogonal functional group or (b) a divalent group comprising no bioorthogonal functional group; and R is a reactive group to the soluble protein; or a salt thereof.
• US9765091B2
  申请人：——

  公开号：US9765091B2

  公开（公告）日：2017-09-19
• [EN] ANTAGONISTS OF GPR39 PROTEIN<br/>[FR] ANTAGONISTES DE LA PROTÉINE GPR39
  申请人：UNIV OREGON HEALTH & SCIENCE

  公开号：WO2021222858A1

  公开（公告）日：2021-11-04

  Novel compounds that act as antagonists to human GPR39 protein are disclosed. Pharmaceutical compositions and methods of use for antagonists to human GPR39 protein are disclosed. In particular, methods of using the antagonists in the treatment of diseases or conditions including cardiovascular conditions, endocrine system and hormone disorders, cancer disorders, metabolic diseases, gastrointestinal and liver diseases, hematological disorders, neurological disorders and respiratory diseases are disclosed herein.